Sofia’s death puts the spotlight back on serious allergies: the functioning of the auto-injector is also under investigation. Meanwhile, the adrenaline nasal spray arrives.
Unfortunately, the news continues to remind us of this with a frequency that cannot leave us indifferent. The death of Sofia di Vico, a fifteen-year-old from Maddaloni who was allergic to milk proteins and probably died due to anaphylactic shock during a dinner in Ostia, brings a well-known yet underestimated topic back to the center of public debate: that of severe food allergies and the risk of fatal anaphylactic shock. According to reconstructions, a vehicle was used to rescue the girl adrenaline auto-injector that she always carried with her, but it remains to be clarified whether the device worked correctly. This aspect is today subject of investigationsan element that adds further complexity to an already dramatic story. In severe food allergies, a minimal quantity of the offending food (an invisible, often undeclared trace) is enough to trigger a violent systemic reaction. The body reacts within minutes: widespread hives, swelling, breathing difficulties appear, up to cardiovascular collapse. In these cases, time is a decisive factor. Without immediate intervention, death can occur quickly.
In Italy they are estimated at approximately 70 deaths per year from anaphylactic shockmany of which are related to food allergies. Numbers that tell of an often invisible reality, made up of incomplete diagnoses, lack of awareness and critical issues in the use of life-saving devices.
Adrenaline and auto-injectors: limits between errors and possible critical issues
Today, the fundamental defense against the anaphylactic shock it is adrenaline administered via autoinjector. These are devices similar to “pens” that patients at risk must always carry with them and use at the first symptoms. Timing is crucial: every minute lost drastically reduces the chances of survival. However, in practice, important critical issues emerge. International studies show that between 20% to 70% of patients use the autoinjector incorrectly. Difficulties may relate to the administration technique, managing panic or unfamiliarity with the device. However, Sofia’s case also opens up another front: that of possible malfunctions. Although rare, any technical problems – such as device defects or inadequate storage – can compromise the effectiveness of the drug. Investigations will clarify whether this played a role in the tragedy, but the doubt alone reinforces the need for increasingly reliable and simple to use devices. Added to this are logistical problems: forget the devicenot having a spare one, or finding yourself in a context where no one knows how to intervene. All elements which, in already dramatic situations, can make the difference between life and death.
Adrenaline nasal spray: the new frontier against anaphylactic shock
In this scenario, the real novelty is represented by new adrenaline nasal sprayalready available in the United States and Germany and awaiting distribution in Italy too. A solution that could respond to the critical issues that have emerged in recent years, including doubts related to the use and reliability of autoinjectors. The spray allows the drug to be administered without a needle, through the nasal mucosa. The advantages are obvious: ease of usespeed of intervention and reduction of the margin of error. Even those without healthcare training can intervene effectively in the first minutes, the decisive ones. Another strong point is the stability of the drugwhich can be stored for up to 30 months, simplifying daily management for patients and families. From a clinical point of view, studies have demonstrated effectiveness comparable to injectionwith an adequate response in allergic emergencies. This innovation could represent a turning point especially in public contexts such as restaurants, schools, workplaces, where the presence of non-healthcare personnel can make timely intervention more difficult. An intuitive and immediate tool can break down many of the barriers that currently limit the correct use of adrenaline. The hope is that the drug will be made available in Italy as soon as possible. Because if it is true that not all tragedies can be avoided, it is equally true that many allergy deaths are preventable. And cases like Sofia’s, for which the judiciary is seeking answers, must become a turning point to improve prevention, training and access to life-saving treatments.
